SCHEMBL20325465

SCHEMBL20325465

COCCCN1CCN(CCCOCCOCCCCN2CCN(CCOC)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.39
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
RECQL P46063 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSD11B1 P28845 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN9A Q15858 1/20 0.34
CHRM2 P08172 1/20 0.34
ADRA2C P18825 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
HRH1 P35367 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27372825 0.98 HRH3 (0.40) HRH3ALDH1A1KDM4ERECQLTDP1
SCHEMBL20231217 0.90 HSD11B1 (0.41) HRH3ALDH1A1HSD11B1USP2HPGD
SCHEMBL20231539 0.90 KDM4E (0.42) ALDH1A1KDM4EHSD11B1SCN9ASMN1; SMN2
SCHEMBL21907884 0.89 ALDH1A1 (0.47) HRH3ALDH1A1KDM4ETDP1HSD11B1
SCHEMBL10930283 0.88 HSD11B1 (0.42) HRH3ALDH1A1KDM4EHSD11B1
SCHEMBL5487629 0.88 KDM4E (0.43) ALDH1A1KDM4EHSD11B1SCN9ASMN1; SMN2
SCHEMBL21673581 0.87 ALDH1A1 (0.46) HRH3ALDH1A1KDM4ETDP1USP2
SCHEMBL20234239 0.86 ALDH1A1 (0.47) HRH3ALDH1A1KDM4EUSP2HPGD
SCHEMBL20234243 0.86 ALDH1A1 (0.45) HRH3ALDH1A1KDM4EUSP2HPGD
SCHEMBL20231219 0.86 ALDH1A1 (0.45) HRH3ALDH1A1KDM4EUSP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL HRH3 3690/4885ALDH1A1 2833/4885KDM4E 3116/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL HRH3 3690/4885ALDH1A1 2833/4885KDM4E 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.